Literature DB >> 8877700

A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists.

V Hariprasad1, V M Kulkarni.   

Abstract

Molecular modeling studies were carried out by a combined use of conformational analysis and 3D-QSAR methods of identify molecular features common to a series of hydroxyacetophenone (HAP) and non-hydroxyacetophenone (non-HAP) peptide leukotriene (pLT) receptor antagonists. In attempts to develop a ligand-binding model for the pLT receptor, the Apex-3D program was used to identify biophoric structural patterns that are common to 13 diverse sets of compounds showing different levels of biological activity. A systematic conformational analysis was carried out to obtain sterically accessible conformations for these flexible compounds. Apex-3D was then utilized to propose common biophoric regions based on the selection of one of several conformations (MOPAC-minimized AM1) from each compound's data set that best fits the biophoric pattern and the resulting superimposition with all the other data-set compounds. Apex-3D identified three common biophoric features important for activity: one as the hydroxyl, acetyl, carbonyl and carboxyl groups, which mimic the acid-binding region of an agonist, the other as the hydrogen-bond donating site, and the third part is represented by a plane in which lipophilic aromatic groups align. The structure-activity relationships were then assessed by using the 3D-QSAR model. A common biophore model is proposed from the Apex-3D analysis which may be useful in designing new pLT antagonists. Molecular volumes and electrostatic potential similarities were also calculated in order to obtain the important structural requirements for the activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877700     DOI: 10.1007/bf00124498

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  13 in total

Review 1.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects.

Authors:  B Samuelsson; S E Dahlén; J A Lindgren; C A Rouzer; C N Serhan
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

2.  Leukotriene receptor antagonists. 4. Synthesis and leukotriene D4/E4 receptor antagonist activity of 4-(alkyl)acetophenone derivatives.

Authors:  D M Gapinski; C R Roman; L E Rinkema; J H Fleisch
Journal:  J Med Chem       Date:  1988-01       Impact factor: 7.446

3.  In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist.

Authors:  D W Snyder; R E Giles; R A Keith; Y K Yee; R D Krell
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

4.  New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships.

Authors:  H Nakai; M Konno; S Kosuge; S Sakuyama; M Toda; Y Arai; T Obata; N Katsube; T Miyamoto; T Okegawa
Journal:  J Med Chem       Date:  1988-01       Impact factor: 7.446

5.  Leukotriene receptor antagonists. 2. The [[(tetrazol-5-ylaryl)oxy]methyl]acetophenone derivatives.

Authors:  R D Dillard; F P Carr; D McCullough; K D Haisch; L E Rinkema; J H Fleisch
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

6.  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.

Authors:  V G Matassa; T P Maduskuie; H S Shapiro; B Hesp; D W Snyder; D Aharony; R D Krell; R A Keith
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

Review 7.  A review of recent contributions on biologically active products of arachidonate conversion.

Authors:  R A Lewis; J M Drazen; J C Figueiredo; E J Corey; K F Austen
Journal:  Int J Immunopharmacol       Date:  1982

8.  Stimulation of human myelopoiesis by leukotrienes B4 and C4: interactions with granulocyte-macrophage colony-stimulating factor.

Authors:  L Stenke; M Mansour; P Reizenstein; J A Lindgren
Journal:  Blood       Date:  1993-01-15       Impact factor: 22.113

9.  Development of a series of phenyltetrazole leukotriene D4 (LTD4) receptor antagonists.

Authors:  R W Harper; D K Herron; N G Bollinger; J S Sawyer; R F Baldwin; C R Roman; L E Rinkema; J H Fleisch
Journal:  J Med Chem       Date:  1992-04-03       Impact factor: 7.446

10.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.

Authors:  B Samuelsson
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.